RXRX RECURSION PHARMACEUTICALS INC

Altitude Lab Startups Raise $154M in Capital

Altitude Lab Startups Raise $154M in Capital

The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones

SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Today, announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Founded by Recursion, Altitude Lab supports diverse life science entrepreneurs in Utah by providing fully equipped laboratories, access to investors, business operations education, and a collaborative founder community.

In addition, Altitude Lab awarded its inaugural to Carmen Kivisild, Ph.D., CEO and founder of . The fellowship provides early-career scientists with up to $150,000 in funding, scientific support, and mentorship to accelerate the growth of their startups.

“Elnora AI is capturing real-world experimental data directly from academic researchers—positive, negative, and everything in between. This enables our AI-powered lab protocol optimizer, helping researchers get their experiments working faster while building the most comprehensive dataset for drug discovery,” said Kivisild. “The Gibson Fellowship gave us critical funding and an anchor community as we relocated from Estonia to Utah. It’s a once-in-a-lifetime opportunity to be mentored by Chris Gibson, Recursion’s CEO and founder, while rapidly scaling Elnora at Altitude Lab.”

Applications for the 2025 Gibson Founder Fellowship are now open.

“In 2025, we anticipate a wave of Series A funding rounds from our alumni and broader founder community,” said Chandana Haque, executive director of Altitude Lab. “Our founders achieved major value inflection points in 2024, and we are thrilled to see them continue scaling.”

Key Milestones from Altitude Lab’s Portfolio:

  • 19 startups in Altitude Lab’s current cohort and 12 alumni
  • 70% of startups are led by at least one underrepresented founder
  • 90% of all participating startups have raised capital
  • Peel Therapeutics completed a Phase 1 trial for its PEEL-224 TOP1 inhibitor and closed the first tranche of its Series A
  • Rebel Medicine received IND approval for Alevatrix and closed the first tranche of its Series A
  • Sethera established Dr. Robert Langer, MIT faculty and co-founder of Moderna, as chair of their Scientific Advisory Board
  • Teiko launched a 25-marker spectral flow cytometry assay on fixed whole blood, combining high-throughput immune measurement of ~150 populations with extended stability for global clinical trials.

Applications to join Altitude Lab’s newest cohort are now open. Learn more and apply for residency and the Founder Fellowship at .

About Altitude Lab

is building a new, representative generation of founders to seed the next cycle of health care innovation in Utah’s BioHive. Currently located in Gateway’s BioHive Hub in Salt Lake City, Altitude Lab is an accelerator program focused on early stage life science and health care companies. The initiative is part of a and collaborative vision from to foster socially-responsible entrepreneurship, job creation, and economic productivity. The Recursion Foundation, under which Altitude Lab operates, is a 501(c)(3) nonprofit organization.

Learn more at or connect on .

About Recursion

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at , or connect on and .



Media Contact
 

Investor Contact
 
EN
18/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RECURSION PHARMACEUTICALS INC

 PRESS RELEASE

Recursion to Participate in Upcoming Investor Conferences

Recursion to Participate in Upcoming Investor Conferences Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Bank of America 2025 Health Care Conference — Tuesday, May 13, 2025 JP Morgan Global Technology, Media and Communications Conference — Thursday, May 15, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at .  About RecursionRecursio...

 PRESS RELEASE

Recursion Reports First Quarter 2025 Financial Results and Provides Bu...

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 clinical programs and 1 preclinical program following a strategic, data-driven reviewPartnerships: Achieved fourth milestone in Sanofi collaboration, generating $7 million for an orally active small-molecule lead with best-in-class potential in autoimmune diseasesPlatform and Operations: Implemented meaningful sy...

 PRESS RELEASE

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyp...

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff.Five of six patients (83%) experienced reductions in polyp burden ranging from 31% to 82%, however, one patient showed a substantial increase from baseline.At Week 13, 50% of patients (3 out of 6) achieved ≥1-point improvement in Spigelman stage, a measure of upper GI disease severity.The early safety profile of REC-48...

 PRESS RELEASE

Recursion to Report First Quarter 2025 Business Updates and Financial ...

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2025 financial results on Monday, May 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 a...

 PRESS RELEASE

Recursion to Present Preliminary Clinical Data from the Ongoing Phase ...

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 (DDW) meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary activity of REC-4881 for the treatment of familial adenomatous polyposis (FAP). The data will be presented as a late-breaking oral presen...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch